Aprea Therapeutics, Inc. (APRE) — Financial statements
Income statement, balance sheet, and cash flow for Aprea Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 2↑157.6% | 0.58 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 9↑132678.5% | 0.01↓100.0% | 16↑5937.4% | 0.27 | |
| Gross Profit | 0.00↑100.0% | -8↓1464.3% | 0.58↑103.5% | -16↓5937.4% | -0.27 | |
| Operating Expenses | ||||||
| R&D Expenses | 7↓24.8% | 9↑22.8% | 8↓91.7% | 92↑286.8% | 24 | |
| General & Administrative Expenses | 6↑0.3% | 6↓23.4% | 8↓59.8% | 21↑54.8% | 14 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.01 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑0.3% | 6↓23.3% | 8↓59.8% | 21↑54.8% | 14 | |
| Other Expenses | -0.29↑96.9% | -9 | 0.00↑100.0% | -16↓5937.4% | -0.27 | |
| Operating Expenses | 13↑104.9% | 6↓59.8% | 16↓83.5% | 97↑160.9% | 37 | |
| Total Costs & Expenses | 13↓16.4% | 16↓1.5% | 16↓85.8% | 113↑202.8% | 37 | |
| Operating Results | ||||||
| Operating Income | -13↑7.6% | -14↑7.4% | -15↑86.4% | -113↓202.8% | -37 | |
| Depreciation & Amortization | 0.02↓2.7% | 0.02↑216.5% | 0.01↑60.2% | 0.00↓98.4% | 0.27 | |
| EBITDA | -13↑7.6% | -14↓0.1% | -14↑61.8% | -37↓1.4% | -37 | |
| EBIT | -13↑7.6% | -14↓0.2% | -14↑61.8% | -37↓0.7% | -37 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.65↓49.4% | 1↑5.3% | 1 | 0.00↓100.0% | 0.00 | |
| Interest Income | 0.65↓49.4% | 1↑5.3% | 1↑172.8% | 0.45↑27124.9% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.45 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -1↑98.4% | -76↓23727.2% | -0.32 | |
| Other Income / Expenses | 0.63↓53.4% | 1↑14.8% | 1↑62.3% | 0.73↑128.9% | 0.32 | |
| Income Before Tax | -13↑2.8% | -13↑9.3% | -14↑87.3% | -113↓203.4% | -37 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -13↑2.8% | -13↑9.3% | -14↑87.3% | -113↓203.4% | -37 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -13↑2.8% | -13↑9.3% | -14↑87.3% | -113↓208.4% | -37 | |
| Bottom-Line Net Income | -13↑2.8% | -13↑9.3% | -14↑87.3% | -113↓203.4% | -37 | |
| EPS (Basic) | -1.93↑17.9% | -2.35↑40.5% | -3.95↑99.7% | -1,359.79↓3798.5% | -34.88 | |
| EPS (Diluted) | -1.93↑17.9% | -2.35↑40.5% | -3.95↑99.7% | -1,359.79↓3798.5% | -34.88 | |
| Weighted Average Shares | 7↑18.7% | 6↑52.3% | 4↑4266.3% | 0.08↓92.2% | 1 | |
| Weighted Average Diluted Shares | 7↑18.7% | 6↑52.3% | 4↑4266.3% | 0.08↓92.2% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.